Deutsche Bank analyst David Hoang lowered the firm’s price target on Harmony Biosciences (HRMY) to $30 from $31 and keeps a Hold rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target lowered to $36 from $46 at UBS
- Harmony Biosciences price target lowered to $28 from $32 at BofA
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership
- Harmony Biosciences reports Q4 adjusted EPS 57c, consensus $1.07
- Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.01B